Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1765: Recurrent fusion of NTRK1 in glioblastoma multiforme.

View through CrossRef
Abstract Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor, yet with no targeted therapy with substantial survival benefit. Recent studies on many types of solid tumors showed that fusion genes often play driver roles and are promising targets for pharmaceutical intervention. To survey potential fusion genes in GBM, we analysed RNA-Seq data from 162 GBM patients available through The Cancer Genome Atlas (TCGA). From the analysis, we identified recurrent fusion of neurotrophic tyrosine kinase receptor type 1 (NTRK1, also called TrkA) to the genes highly expressed in neuronal tissues, neurofascin (NFASC) and brevican (BCAN). NTRK1 is a mediator of the pro-survival signaling of nerve growth factor (NGF) and is a known oncogene, found commonly altered in human cancer. While GBMs largely lack NTRK1 expression, the fusion-positive GBMs express fusion transcripts in high abundance that retain NTRK1 kinase domain in frame. Analyses of the matching Exome-Seq data indicated that NFASC-NTRK1 fusion occurred through DNA-level rearrangement, whereas BCAN-NTRK1 fusion presumably occurred at RNA-level. As analogous NTRK1-fusions with thyroid-expressed genes were previously shown to drive thyroid cancer, NTRK1-fusion in GBM might have a similar role. Consistent with this hypothesis, the GBMs that harbor the NTRK1-fusion showed elevated NGF/NTRK1 pathway activity. About 1% of GBM patients are estimated to have NTRK1-fusion; these patients might benefit from potential NTRK1 inhibition therapies. Citation Format: Jinkuk Kim, Hee-Jin Cho, Gye-Hyun Cho, Young-Hyeh Ko, Soonmyung Paik, Do-Hyun Nam. Recurrent fusion of NTRK1 in glioblastoma multiforme. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1765. doi:10.1158/1538-7445.AM2013-1765 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Title: Abstract 1765: Recurrent fusion of NTRK1 in glioblastoma multiforme.
Description:
Abstract Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor, yet with no targeted therapy with substantial survival benefit.
Recent studies on many types of solid tumors showed that fusion genes often play driver roles and are promising targets for pharmaceutical intervention.
To survey potential fusion genes in GBM, we analysed RNA-Seq data from 162 GBM patients available through The Cancer Genome Atlas (TCGA).
From the analysis, we identified recurrent fusion of neurotrophic tyrosine kinase receptor type 1 (NTRK1, also called TrkA) to the genes highly expressed in neuronal tissues, neurofascin (NFASC) and brevican (BCAN).
NTRK1 is a mediator of the pro-survival signaling of nerve growth factor (NGF) and is a known oncogene, found commonly altered in human cancer.
While GBMs largely lack NTRK1 expression, the fusion-positive GBMs express fusion transcripts in high abundance that retain NTRK1 kinase domain in frame.
Analyses of the matching Exome-Seq data indicated that NFASC-NTRK1 fusion occurred through DNA-level rearrangement, whereas BCAN-NTRK1 fusion presumably occurred at RNA-level.
As analogous NTRK1-fusions with thyroid-expressed genes were previously shown to drive thyroid cancer, NTRK1-fusion in GBM might have a similar role.
Consistent with this hypothesis, the GBMs that harbor the NTRK1-fusion showed elevated NGF/NTRK1 pathway activity.
About 1% of GBM patients are estimated to have NTRK1-fusion; these patients might benefit from potential NTRK1 inhibition therapies.
Citation Format: Jinkuk Kim, Hee-Jin Cho, Gye-Hyun Cho, Young-Hyeh Ko, Soonmyung Paik, Do-Hyun Nam.
Recurrent fusion of NTRK1 in glioblastoma multiforme.
[abstract].
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1765.
doi:10.
1158/1538-7445.
AM2013-1765 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.

Related Results

The Nuclear Fusion Award
The Nuclear Fusion Award
The Nuclear Fusion Award ceremony for 2009 and 2010 award winners was held during the 23rd IAEA Fusion Energy Conference in Daejeon. This time, both 2009 and 2010 award winners w...
Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma
Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma
Abstract Background The genetic background of papillary thyroid carcinoma (PTC) has been elucidated by the identification of som...
BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression
BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression
Abstract Glioblastoma is the most common malignant brain tumor in adults. Cellular plasticity and the poorly differentiated features result in a ...
Intermittent oral cyclosporin for recurrent herpes simplex‐associated erythema multiforme
Intermittent oral cyclosporin for recurrent herpes simplex‐associated erythema multiforme
SUMMARYRecurrent erythema multiforme is one of three distinct clinical subtypes of erythema multiforme. We present a 42‐year‐old man with a 10‐year history of recurrent herpes simp...
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract Background: The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma ...
Nonproliferation and fusion power plants
Nonproliferation and fusion power plants
Abstract The world now appears to be on the brink of realizing commercial fusion. As fusion energy progresses towards near-term commercial deployment, the question arises a...
P10.36.B ROLE OF AMPK IN GLIOBLASTOMA BIOENERGETICS
P10.36.B ROLE OF AMPK IN GLIOBLASTOMA BIOENERGETICS
Abstract BACKGROUND Glioblastoma is the most prevalent and aggressive primary brain tumor. AMP-activated kinase (AMPK), the main...

Back to Top